Cargando…

Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials

Telmisartan is indicated for the prevention of cardiovascular events in high-risk patients, based on comparable efficacy to the angiotensin-converting enzyme (ACE) inhibitor, ramipril, in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET(®)) trial. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mancia, Giuseppe, Schumacher, Helmut
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262485/ https://www.ncbi.nlm.nih.gov/pubmed/22272064 http://dx.doi.org/10.2147/PPA.S27939

Ejemplares similares

Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy
por: Neldam, Steen, et al.
Publicado: (2013)

Effects of Telmisartan with Hydrochlorothiazide versus Valsartan with Hydrochlorothiazide in Patients with Moderate-to-Severe Hypertension
por: Marfatia, Ravi, et al.
Publicado: (2012)

Telmisartan and cardioprotection
por: Akhrass, Philippe R, et al.
Publicado: (2011)

Critical appraisal and pooled analysis of telmisartan alone or in combination with hydrochlorothiazide for achieving blood pressure goals
por: Morimoto, Satoshi, et al.
Publicado: (2010)

Telmisartan Self-Nanoemulsifying Drug Delivery System, Compared With Standard Telmisartan, More Effectively Improves Hepatic Fibrosis in Rats
por: Murad, Hussam, et al.
Publicado: (2020)

Efficacy and Tolerability of Telmisartan Plus Amlodipine in Asian Patients Not Adequately Controlled on Either Monotherapy or on Low-Dose Combination Therapy
por: Zhu, Dingliang, et al.
Publicado: (2014)

Effect of a fixed-dose combination of Telmisartan/S-amlodipine on circadian blood pressure compared with Telmisartan monotherapy: TENUVA-BP study
por: Kim, Bong-Joon, et al.
Publicado: (2022)

What is the impact of the ACE gene insertion/deletion (I/D) polymorphism on the clinical effectiveness and adverse events of ACE inhibitors? – Protocol of a systematic review
por: Scharplatz, M, et al.
Publicado: (2004)

A Pilot Study of Telmisartan for Visceral Adiposity in HIV Infection: The Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial
por: Lake, Jordan E., et al.
Publicado: (2013)

Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
por: Hirata, Takumi, et al.
Publicado: (2013)

Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT
por: Falcone, Colomba, et al.
Publicado: (2012)

Montelukast and Telmisartan as Inhibitors of SARS-CoV-2 Omicron Variant
por: Mulgaonkar, Nirmitee, et al.
Publicado: (2023)

Evidence for an effect of ACE inhibitors on cancer cachexia
por: Schanze, Nancy, et al.
Publicado: (2012)

Erratum to “Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)”
por: Hirata, Takumi, et al.
Publicado: (2014)

Efficient and improved synthesis of Telmisartan
por: Kumar, A Sanjeev, et al.
Publicado: (2010)

Telmisartan induced urticarial vasculitis
por: Mahajan, Vikram K., et al.
Publicado: (2015)

Telmisartan/hydrochlorothiazide-induced hepatotoxicity
por: Lorena, Marco, et al.
Publicado: (2015)

Telmisartan aggravates pustular psoriasis
por: Keerthi, Subramaniam, et al.
Publicado: (2015)

The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
por: Owczarek, Witold, et al.
Publicado: (2017)

Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril
por: Wang, Ji-Guang, et al.
Publicado: (2014)

Incidence of seizure exacerbation and seizures reported as adverse events during adjunctive treatment with eslicarbazepine acetate: A pooled analysis of three Phase III controlled trials
por: Carreño, Mar, et al.
Publicado: (2017)

β‐blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy
por: Sturm, Gunter Johannes, et al.
Publicado: (2021)

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome
por: Vitale, Cristiana, et al.
Publicado: (2005)

Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials
por: Chalmers, John, et al.
Publicado: (2023)

Urine Eicosanoids in the Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial
por: Le, Catherine N., et al.
Publicado: (2017)

Impact of telmisartan in modifying vascular risk
por: Baguet, Jean-Philippe, et al.
Publicado: (2010)

Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes: The TRANSCEND study
por: Barzilay, Joshua I., et al.
Publicado: (2011)

Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature
por: Boutros, A., et al.
Publicado: (2023)

Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial
por: Duarte, Mariano, et al.
Publicado: (2021)

Proniosomal Telmisartan Tablets: Formulation, in vitro Evaluation and in vivo Comparative Pharmacokinetic Study in Rabbits
por: Teaima, Mahmoud Hasan, et al.
Publicado: (2020)

Renovascular and renoprotective properties of telmisartan: clinical utility
por: Ladino, Marco, et al.
Publicado: (2010)

RP-HPLC Estimation of Ramipril and Telmisartan in Tablets
por: Kurade, V. P., et al.
Publicado: (2009)

Polymorphism of ORM1 Is Associated with the Pharmacokinetics of Telmisartan
por: Chen, Wang-Qing, et al.
Publicado: (2013)

Telmisartan Treatment of Refractory Proteinuria in a Dog
por: Bugbee, A.C., et al.
Publicado: (2014)

Efficacy and Safety of Azilsartan and Telmisartan in Hypertensive Patients
por: Kumar, Alok, et al.
Publicado: (2021)

Telmisartan Attenuates Kanamycin-Induced Ototoxicity in Rats
por: Lee, Chang Ho, et al.
Publicado: (2021)

ACE-Inhibitor Related Angioedema Is Not Sufficiently Reported to the Danish Adverse Drug Reactions Database
por: Cornwall, Johan Emil Lundbek, et al.
Publicado: (2019)

Dose response of ACE inhibitors: implications of the SECURE trial
por: Lonn, Eva
Publicado: (2001)

Incidence of adverse events in a Brazilian coronary ICU
por: Paula, VF, et al.
Publicado: (2014)

Adverse Events in Patients with Blood Loss: A Pooled Analysis of 51 Clinical Studies from the Celecoxib Clinical Trial Database
por: Sands, GH, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j4k0g0m5mq580fipj7dsnub75i